 | • レポートコード：MRC2303F0155 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、223ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料は、2021年に185.3億ドルであった世界の鎮痛剤市場規模が、2022年に201.1億ドルになり、2027年まで年平均8.69%で成長して305.6億ドルに到達すると予想しています。本調査資料では、鎮痛剤の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬物タイプ別（アセトアミノフェン、非ステロイド性抗炎症薬、サリチル酸塩）分析、種類別（非オピオイド、オピオイド）分析、投与経路別（静脈内、経口、直腸、局所、経皮吸収）分析、流通別（病院薬局、オンライン薬局、小売薬局）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。さらに、市場参入企業として、7T Pharma LLC、Abbott Laboratories、AbbVie Inc.、Amphastar Pharmaceuticals, Inc.、Aspen Pharmacare Holdings Limited、Astrazeneca PLC、Avir Pharma Inc、B. Braun Melsungen AG、Baxter International Inc.、Boehringer Ingelheim International GmbH、Braun Melsungen AG、Cantrell Drug Company、Cipher Pharmaceuticals Inc.、Cipla USA Inc.、Claris Life sciences、Eisai Co. Ltd.、Exelan Pharmaceuticals, Inc.、F. Hoffmann-La Roche Ltd、Fresenius Kabi USA, LLC、Glenmark Pharmaceuticals Limitedなどの情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の鎮痛剤市場規模：薬物タイプ別 - アセトアミノフェンの市場規模 - 非ステロイド性抗炎症薬の市場規模 - サリチル酸塩の市場規模 ・世界の鎮痛剤市場規模：種類別 - 非オピオイド鎮痛剤の市場規模 - オピオイド鎮痛剤の市場規模 ・世界の鎮痛剤市場規模：投与経路別 - 静脈内鎮痛剤の市場規模 - 経口鎮痛剤の市場規模 - 直腸鎮痛剤の市場規模 - 局所鎮痛剤の市場規模 - 経皮吸収鎮痛剤の市場規模 ・世界の鎮痛剤市場規模：流通別 - 病院薬局チャネルの市場規模 - オンライン薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界の鎮痛剤市場規模：地域別 - 南北アメリカの鎮痛剤市場規模 アメリカの鎮痛剤市場規模 カナダの鎮痛剤市場規模 ブラジルの鎮痛剤市場規模 ... - アジア太平洋の鎮痛剤市場規模 日本の鎮痛剤市場規模 中国の鎮痛剤市場規模 インドの鎮痛剤市場規模 韓国の鎮痛剤市場規模 台湾の鎮痛剤市場規模 ... -ヨーロッパ/中東/アフリカの鎮痛剤市場規模 イギリスの鎮痛剤市場規模 ドイツの鎮痛剤市場規模 フランスの鎮痛剤市場規模 ロシアの鎮痛剤市場規模 ... -その他地域の鎮痛剤市場規模 ・競争状況 ・企業情報 |
The Global Analgesics Market size was estimated at USD 18.53 billion in 2021 and expected to reach USD 20.11 billion in 2022, and is projected to grow at a CAGR 8.69% to reach USD 30.56 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Analgesics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the market was studied across Acetaminophen, Nonsteroidal Anti-inflammatory Drugs (NSAIDs), and Salicylates.
Based on Type, the market was studied across Non-opioids and Opioids.
Based on Route of Administration, the market was studied across Intravenous, Oral, Rectal, Topical, and Transdermal.
Based on Distribution, the market was studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Analgesics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Analgesics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Analgesics Market, including 7T Pharma LLC, Abbott Laboratories, AbbVie Inc., Amphastar Pharmaceuticals, Inc., Aspen Pharmacare Holdings Limited, Astrazeneca PLC, Avir Pharma Inc, B. Braun Melsungen AG, Baxter International Inc., Boehringer Ingelheim International GmbH, Braun Melsungen AG, Cantrell Drug Company, Cipher Pharmaceuticals Inc., Cipla USA Inc., Claris Life sciences, Eisai Co. Ltd., Exelan Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Fresenius Kabi USA, LLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Hospira, Inc., Leucadia Pharmaceuticals, Maruishi Pharmaceutical Co., Ltd., Mylan Institutional LLC, Pacira Pharmaceuticals, Inc., Paion UK Ltd, Pfizer Inc., Piramal Enterprises LTD, Remedy Repack, Sandoz Inc, Septodont, Stat Rx USA, Teva Pharmaceutical Industries Limited, Troikaa Pharmaceuticals Ltd, Vertical Pharmaceuticals, Inc., and West-Ward Pharmaceuticals Corp.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Analgesics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Analgesics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Analgesics Market?
4. What is the competitive strategic window for opportunities in the Global Analgesics Market?
5. What are the technology trends and regulatory frameworks in the Global Analgesics Market?
6. What is the market share of the leading vendors in the Global Analgesics Market?
7. What modes and strategic moves are considered suitable for entering the Global Analgesics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of cardiovascular disease (CVD), cancer, & arthritis
5.1.1.2. Frequent pain and aches encountered by the aging population
5.1.1.3. Cost-efficiency of OTC analgesics drugs
5.1.2. Restraints
5.1.2.1. Uncontrolled prescriptions of opioids and drug abuse
5.1.3. Opportunities
5.1.3.1. Increasing investments in R&D by the public & private sectors
5.1.3.2. Surge in popularity of personalized medicine
5.1.4. Challenges
5.1.4.1. Limited availability and affordability of high efficacy drugs, including opioid analgesics
5.2. Cumulative Impact of COVID-19
6. Analgesics Market, by Drug Type
6.1. Introduction
6.2. Acetaminophen
6.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
6.4. Salicylates
7. Analgesics Market, by Type
7.1. Introduction
7.2. Non-opioids
7.3. Opioids
8. Analgesics Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Rectal
8.5. Topical
8.6. Transdermal
9. Analgesics Market, by Distribution
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Americas Analgesics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Analgesics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Analgesics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. 7T Pharma LLC
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Abbott Laboratories
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. AbbVie Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Amphastar Pharmaceuticals, Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Aspen Pharmacare Holdings Limited
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Astrazeneca PLC
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Avir Pharma Inc
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. B. Braun Melsungen AG
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Baxter International Inc.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Boehringer Ingelheim International GmbH
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Braun Melsungen AG
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Cantrell Drug Company
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Cipher Pharmaceuticals Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Cipla USA Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Claris Life sciences
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Eisai Co. Ltd.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Exelan Pharmaceuticals, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. F. Hoffmann-La Roche Ltd
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Fresenius Kabi USA, LLC
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Glenmark Pharmaceuticals Limited
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Hikma Pharmaceuticals PLC
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Hospira, Inc.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Leucadia Pharmaceuticals
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Maruishi Pharmaceutical Co., Ltd.
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Mylan Institutional LLC
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. Pacira Pharmaceuticals, Inc.
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
14.27. Paion UK Ltd
14.27.1. Business Overview
14.27.2. Key Executives
14.27.3. Product & Services
14.28. Pfizer Inc.
14.28.1. Business Overview
14.28.2. Key Executives
14.28.3. Product & Services
14.29. Piramal Enterprises LTD
14.29.1. Business Overview
14.29.2. Key Executives
14.29.3. Product & Services
14.30. Remedy Repack
14.30.1. Business Overview
14.30.2. Key Executives
14.30.3. Product & Services
14.31. Sandoz Inc
14.31.1. Business Overview
14.31.2. Key Executives
14.31.3. Product & Services
14.32. Septodont
14.32.1. Business Overview
14.32.2. Key Executives
14.32.3. Product & Services
14.33. Stat Rx USA
14.33.1. Business Overview
14.33.2. Key Executives
14.33.3. Product & Services
14.34. Teva Pharmaceutical Industries Limited
14.34.1. Business Overview
14.34.2. Key Executives
14.34.3. Product & Services
14.35. Troikaa Pharmaceuticals Ltd
14.35.1. Business Overview
14.35.2. Key Executives
14.35.3. Product & Services
14.36. Vertical Pharmaceuticals, Inc.
14.36.1. Business Overview
14.36.2. Key Executives
14.36.3. Product & Services
14.37. West-Ward Pharmaceuticals Corp
14.37.1. Business Overview
14.37.2. Key Executives
14.37.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing